No vaccine at present incorporates all known respiratory pathogens, although vaccines are available against the principal pathogens.
CDV vaccination should be given routinely (for details see preceding chapter ).
- Either CAV-1 or CAV-2 vaccine protect against CAV-1- or CAV-2- induced-respiratory disease (and ICH).
- CAV-2 has now virtually replaced CAV- 1 in modified live canine adenovirus vaccines as it does not induce blue eye, possible viral persistence with lesions in the kidney, and viral excretion in the urine.
- Inactivated vaccines for CAV infection are also available.
- Maternally derived antibody may interfere with successful vaccination. Thus, although vaccination may be carried out from 6 to 8 weeks of age, a second dose should always be given at 12 weeks of age. Experimental intranasal vaccines have been developed which would overcome MDA, but are not commercially available and in any case are not generally necessary.
- Although immunity following live virus vaccination probably lasts several years 1-to 2 -yearly boosters are generally recommended; annual boosters are required for inactivated vaccines.
B. bronchiseptica vaccination:
Back to menu